JP2017512803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512803A5 JP2017512803A5 JP2016559879A JP2016559879A JP2017512803A5 JP 2017512803 A5 JP2017512803 A5 JP 2017512803A5 JP 2016559879 A JP2016559879 A JP 2016559879A JP 2016559879 A JP2016559879 A JP 2016559879A JP 2017512803 A5 JP2017512803 A5 JP 2017512803A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- hydroxy
- halo
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 80
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 48
- 229910052736 halogen Inorganic materials 0.000 claims 38
- 150000002367 halogens Chemical class 0.000 claims 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 34
- 125000001424 substituent group Chemical group 0.000 claims 29
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 25
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 150000001721 carbon Chemical group 0.000 claims 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 20
- 125000001153 fluoro group Chemical group F* 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- -1 cyano, hydroxy Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 229910052760 oxygen Chemical group 0.000 claims 3
- 239000001301 oxygen Chemical group 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000006006 difluoroethoxy group Chemical group 0.000 claims 2
- 125000006005 fluoroethoxy group Chemical group 0.000 claims 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- SIQJUJBSEDNWPI-UHFFFAOYSA-N CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C Chemical compound CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C SIQJUJBSEDNWPI-UHFFFAOYSA-N 0.000 claims 1
- NGCLDKLLCXHWGU-UHFFFAOYSA-N CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)OC(F)(F)F)C Chemical compound CC1(OC2=CC=C(C=C2C(=C1)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)OC(F)(F)F)C NGCLDKLLCXHWGU-UHFFFAOYSA-N 0.000 claims 1
- OXAMLWSJBGIHNL-INIZCTEOSA-N CC1(OC2=CC=C(C=C2C(=C1)[C@H](C)N1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C Chemical compound CC1(OC2=CC=C(C=C2C(=C1)[C@H](C)N1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O)C(F)(F)F)C OXAMLWSJBGIHNL-INIZCTEOSA-N 0.000 claims 1
- LHTSLMHEFKNOOX-PXDATVDWSA-N CC1(OC=2C=CC(=CC2[C@]2([C@@H]1C2)CN2C(C=1N(CC2)C(C(=CC1)N1C=NC(=C1)C)=O)=O)C(F)(F)F)C Chemical compound CC1(OC=2C=CC(=CC2[C@]2([C@@H]1C2)CN2C(C=1N(CC2)C(C(=CC1)N1C=NC(=C1)C)=O)=O)C(F)(F)F)C LHTSLMHEFKNOOX-PXDATVDWSA-N 0.000 claims 1
- ORLKJYBPSXUASX-PXDATVDWSA-N CC1(OC=2C=CC(=CC2[C@]2([C@@H]1C2)CN2C(C=1N(CC2)C(C(=CC1)N1C=NC(=C1)C)=O)=O)OC(F)(F)F)C Chemical compound CC1(OC=2C=CC(=CC2[C@]2([C@@H]1C2)CN2C(C=1N(CC2)C(C(=CC1)N1C=NC(=C1)C)=O)=O)OC(F)(F)F)C ORLKJYBPSXUASX-PXDATVDWSA-N 0.000 claims 1
- MLZHNNLTXCDNLL-AVRWGWEMSA-N CC=1N=CN(C1)C1=CC=C2N(CCN(C2=O)C[C@]23[C@H](COC=4C=CC(=CC24)C2(CC2)C(F)(F)F)C3)C1=O Chemical compound CC=1N=CN(C1)C1=CC=C2N(CCN(C2=O)C[C@]23[C@H](COC=4C=CC(=CC24)C2(CC2)C(F)(F)F)C3)C1=O MLZHNNLTXCDNLL-AVRWGWEMSA-N 0.000 claims 1
- FRPPYXDKNYDZHE-CMJOXMDJSA-N ClC1=CC(=CC=2[C@]3([C@@H](COC12)C3)CN3C(C=1N(CC3)C(C(=CC1)N1C=NC(=C1)C)=O)=O)C(F)(F)F Chemical compound ClC1=CC(=CC=2[C@]3([C@@H](COC12)C3)CN3C(C=1N(CC3)C(C(=CC1)N1C=NC(=C1)C)=O)=O)C(F)(F)F FRPPYXDKNYDZHE-CMJOXMDJSA-N 0.000 claims 1
- MZPMUGOGQIVILU-UHFFFAOYSA-N ClC=1C=C2C(=CC(OC2=C(C1)F)(C)C)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O Chemical compound ClC=1C=C2C(=CC(OC2=C(C1)F)(C)C)CN1C(C=2N(CC1)C(C(=CC2)N2C=NC(=C2)C)=O)=O MZPMUGOGQIVILU-UHFFFAOYSA-N 0.000 claims 1
- LCNNBFCDMJIFBF-CPJLOUKISA-N FC(C)(OC1=CC=2[C@]3([C@@H](COC2C=C1)C3)CN3C(C=1N(CC3)C(C(=CC1)N1C=NC(=C1)C)=O)=O)F Chemical compound FC(C)(OC1=CC=2[C@]3([C@@H](COC2C=C1)C3)CN3C(C=1N(CC3)C(C(=CC1)N1C=NC(=C1)C)=O)=O)F LCNNBFCDMJIFBF-CPJLOUKISA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973436P | 2014-04-01 | 2014-04-01 | |
| US61/973,436 | 2014-04-01 | ||
| PCT/IB2015/051988 WO2015150957A1 (en) | 2014-04-01 | 2015-03-18 | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512803A JP2017512803A (ja) | 2017-05-25 |
| JP2017512803A5 true JP2017512803A5 (cg-RX-API-DMAC7.html) | 2018-04-26 |
| JP6643247B2 JP6643247B2 (ja) | 2020-02-12 |
Family
ID=52815058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559879A Expired - Fee Related JP6643247B2 (ja) | 2014-04-01 | 2015-03-18 | ガンマセクレターゼモジュレーターとしてのクロメンおよび１，１ａ，２，７Ｂ−テトラヒドロシクロプロパ［Ｃ］クロメンピリドピラジンジオン |
Country Status (29)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2016125048A1 (en) * | 2015-02-03 | 2016-08-11 | Pfizer Inc. | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| CN106580997B (zh) * | 2016-12-09 | 2018-01-19 | 张田 | 一种治疗先兆流产的药物组合物 |
| US10925872B2 (en) | 2016-12-16 | 2021-02-23 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
| AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| CN110907542A (zh) * | 2018-09-17 | 2020-03-24 | 复旦大学 | 一种液质联用检测唾液中司来吉兰及其代谢物的方法 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| TWI867053B (zh) | 2019-09-26 | 2024-12-21 | 瑞士商諾華公司 | 抗病毒吡唑并吡啶酮化合物 |
| AU2023364628A1 (en) | 2022-10-18 | 2025-04-03 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
| WO2024084363A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Use of patatin-like phospholipase domain-containing protein 3 compounds |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| JP3816111B2 (ja) | 1997-04-09 | 2006-08-30 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法 |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| SI1481992T1 (sl) | 2000-02-24 | 2017-01-31 | Washington University St. Louis | Humanizirana protitelesa, ki vežejo amiloidni peptid beta |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| JP4708675B2 (ja) | 2000-11-03 | 2011-06-22 | プロテオテック・インコーポレーテッド | ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用 |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| WO2003072579A1 (en) * | 2002-02-28 | 2003-09-04 | Sanofi-Aventis | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| PL1881985T3 (pl) | 2005-05-12 | 2011-05-31 | Pfizer | Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006136924A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| CA2649775C (en) | 2006-04-21 | 2011-05-31 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008090429A1 (en) | 2007-01-22 | 2008-07-31 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| JP2012506857A (ja) * | 2008-10-23 | 2012-03-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子 |
| ES2602794T3 (es) | 2011-03-31 | 2017-02-22 | Pfizer Inc | Piridinonas bicíclicas novedosas |
| AU2013261023B2 (en) * | 2012-05-16 | 2016-11-24 | Cellzome Limited | Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease |
| UA110688C2 (uk) * | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2945944B1 (en) * | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
| EP3052495B1 (en) * | 2013-10-04 | 2019-06-26 | Pfizer Inc | Novel bicyclic pyridinones as gamma-secretase modulators |
-
2015
- 2015-03-18 WO PCT/IB2015/051988 patent/WO2015150957A1/en not_active Ceased
- 2015-03-18 AP AP2016009465A patent/AP2016009465A0/en unknown
- 2015-03-18 BR BR112016022519A patent/BR112016022519A8/pt not_active IP Right Cessation
- 2015-03-18 PE PE2016001895A patent/PE20161364A1/es not_active Application Discontinuation
- 2015-03-18 AU AU2015242330A patent/AU2015242330B2/en not_active Ceased
- 2015-03-18 CA CA2944308A patent/CA2944308A1/en not_active Withdrawn
- 2015-03-18 DK DK15714951.9T patent/DK3126361T3/da active
- 2015-03-18 KR KR1020167030135A patent/KR101886945B1/ko not_active Expired - Fee Related
- 2015-03-18 ES ES15714951T patent/ES2759277T3/es active Active
- 2015-03-18 JP JP2016559879A patent/JP6643247B2/ja not_active Expired - Fee Related
- 2015-03-18 EA EA201600619A patent/EA031419B1/ru not_active IP Right Cessation
- 2015-03-18 CN CN201580018466.7A patent/CN106211770B/zh not_active Expired - Fee Related
- 2015-03-18 MD MDA20160102A patent/MD20160102A2/ro not_active Application Discontinuation
- 2015-03-18 EP EP15714951.9A patent/EP3126361B1/en active Active
- 2015-03-18 SG SG11201607465UA patent/SG11201607465UA/en unknown
- 2015-03-18 CR CR20160454A patent/CR20160454A/es unknown
- 2015-03-18 MX MX2016012904A patent/MX369074B/es active IP Right Grant
- 2015-03-27 UY UY0001036054A patent/UY36054A/es not_active Application Discontinuation
- 2015-03-27 AR ARP150100922A patent/AR099874A1/es unknown
- 2015-03-27 US US14/670,746 patent/US20150274721A1/en not_active Abandoned
- 2015-03-31 TW TW104110551A patent/TWI568733B/zh not_active IP Right Cessation
-
2016
- 2016-09-09 ZA ZA2016/06252A patent/ZA201606252B/en unknown
- 2016-09-22 PH PH12016501864A patent/PH12016501864A1/en unknown
- 2016-09-22 CU CUP2016000140A patent/CU20160140A7/es unknown
- 2016-09-27 CL CL2016002422A patent/CL2016002422A1/es unknown
- 2016-09-29 IL IL248154A patent/IL248154B/en active IP Right Grant
- 2016-09-29 NI NI201600149A patent/NI201600149A/es unknown
- 2016-09-29 DO DO2016000266A patent/DOP2016000266A/es unknown
- 2016-09-30 EC ECIEPI201678289A patent/ECSP16078289A/es unknown
-
2017
- 2017-02-24 US US15/441,882 patent/US20170166566A1/en not_active Abandoned